Entity

Time filter

Source Type


Huang Z.-Z.,U.S. Center for Disease Control and Prevention | Chen W.-Q.,Chinese Academy of Sciences | Wu C.-X.,U.S. Center for Disease Control and Prevention | Zheng R.-S.,Chinese Academy of Sciences | And 5 more authors.
Tumor | Year: 2012

Objective: To analyze the trends of female breast cancer incidence and mortality in Beijing, Shanghai, Linzhou and Qidong in China between 1988 and 2007. Methods: The data of female breast cancer incidence and mortality and the data of corresponding population during 1988-2007 were collected from four eligible cancer registries which could provide complete sets of historical data. The pooled analysis and time-trend analysis of the data were performed. Results: During 1988-2007, the APCs (annual percent changes) of age-standardized incidence rates (by China's population in 1982) of female breast cancer in Beijing, Shanghai, Linzhou and Qidong were 2.49%, 2.55%, 7.04% and 4.16%, respectively. Although the average annual growth of APC of age-standardized mortality was 4.10% in Linzhou, there were no significant changes in Beijing, Shanghai and Qidong. Conclusion: During 1988-2007, the breast cancer incidence and mortality of the urban women in Beijing and Shanghai were significantly higher than those of the rural women in Linzhou and Qidong. The incidence rate of female breast cancer in these four areas showed an obvious rising trend, and this increase was more significant in rural areas. The mortality rate of female breast cancer in Linzhou also showed a rising trend, but the mortality rates in the other three areas remained steady. Copyright © 2012 by TUMOR. Source


Huang Z.-Z.,U.S. Center for Disease Control and Prevention | Chen W.-Q.,Chinese Academy of Sciences | Wu C.-X.,U.S. Center for Disease Control and Prevention | Zheng R.-S.,Chinese Academy of Sciences | And 5 more authors.
Tumor | Year: 2012

Objective: To describe the incidence and mortality of female breast cancer in China during 2003-2007. Methods: The incidence and mortality data of female breast cancer and the corresponding population data from 32 eligible cancer registries in China during 2003-2007 were collected and analyzed. Results: The combined crude incidence rate of female breast cancer during 2003-2007 was 41.64 per 100 000, which was the highest among female cancer incidence rates. The combined crude mortality rate of female breast cancer was 9.63 per 100 000, which was ranked as the sixth among the mortality rates of all female cancers. The incidence rate was 3.04 times higher and the mortality rate was 1.92 times higher in urban areas than those in rural areas. Compared to the incidence and mortality rates of 184 regions provided from GLABOCAN 2008 database, the female breast cancer incidence in China was ranked as the one hundred and tenth, and the mortality was ranked as the one hundred and seventy-second. Conclusion: Breast cancer has been becoming one of the most common cancers among Chinese women. The incidence and mortality rates of female breast cancer in urban areas are significantly higher than those in rural areas, although the overall incidence and mortality rates of breast cancer in Chinese women are still at a medium or low level in the world. © 2012 by Tumor. Source


The invention provides a primer group for detecting CpO island methylation of p16 gene using methylation specific fluorescence technique. The primer group comprises a pair of oligonucleotide primers and a fluorescence-labeled probe. Said oligonucleotide primer pair has base sequence represented by SEQ ID NO.1 and SEQ ID NO.2. Said fluorescence-labeled probe has base sequence represented by SEQ ID NO.3 or SEQ NO.4.


Provided in the present invention are a method using in vitro measurement of the content of methylation or demethylation of GFRal CpG islands to estimate a risk of tumorigenesis and of tumor metastasis, or postoperative life expectancy, and a nucleotide sequence used.


Wang Z.,Beijing Institute for Cancer Research | Shen Z.,China National Institute of Biological Sciences | Shen Z.,Shanghai JiaoTong University | Li Z.,Beijing Institute for Cancer Research | And 10 more authors.
Proceedings of the National Academy of Sciences of the United States of America | Year: 2015

The empirical criteria for defining a clinical subtype of lung cancer are gradually transiting from histopathology to genetic variations in driver genes. Targeting these driver mutations, such as sensitizing epidermal growth factor receptor (EGFR) mutations, has dramatically improved the prognosis of advanced non-small cell lung cancer (NSCLC). However, the clinical benefit of molecularly targeted therapy on NSCLC appears to be different between lung adenocarcinomas and squamous cell carcinomas (SqCCs). We report here that the resistance of lung SqCC harboring EGFR mutations to EGFR tyrosine kinase inhibitors (EGFR-TKIs) was due to the activation of BMP-BMPR-Smad1/5-p70S6K. The combined treatment of these tumor cells with EGFR-TKI, together with inhibitors specific to BMPR or downstream mTOR, effectively reversed the resistance to EGFR-TKI. Moreover, blocking the whole PI3K-AKTmTOR pathway with the PI3K/mTOR dual inhibitor BEZ235 also showed efficacy in treating this subtype of lung SqCC. This study details the empirical basis for a feasible clinical solution for squamous cell carcinomas with EGFR mutations. Source

Discover hidden collaborations